Table 1.

Assessment of therapeutic synergism using the FTV calculation method. The expected FTV (i.e., the product of FTV values for monotherapies (ONCOS-102 or Pembrolizumab)) of the combination therapy (ONCOS-102 plus Pembrolizumab) is divided by the observed FTV of the combination, yielding a ratio that indicates the nature of the interaction (> 1 indicates synergy and < 1 indicates a less than additive effect). FTV foreach experimental group is obtained by dividing the mean tumor volume of the experimental group (ONCOS-102 or Pembrolizumab) by the mean tumor volume of the control group (mock).

Day	FTV for monotherapy			ONCOS-102 + Pembro 200 μg			ONCOS-102 + Pembro 400 μg
	Pembro 200 μg	Pembro 400 μg	ONCOS-102	Expected FTV	Observed FTV	Ratio (Expected/ Observed)	Expected FTV	Observed FTV	Ratio (Expected/ Observed)
26	0,95	0,87	0,88	0,83	0,76	1,1	0,77	0,87	0,88
37	0,91	1,26	0,68	0,62	0,42	1,47	0,86	0,40	2,14